Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
8
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.4% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Digi International
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Subscription And Cloud Demand Will Secure Long-Term Market Value
Key Takeaways Shift to subscription and recurring revenue models, combined with increased demand for secure edge solutions, is boosting revenue stability, margins, and customer retention. Agile supply chain management and M&A focus provide competitive advantages, supporting profitability, reliable hardware supply, and scalable long-term growth.
View narrative
US$39.67
FV
18.7% undervalued
intrinsic discount
3.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
5 days ago
author updated this narrative
IMAX
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
North America And Japan Installations Will Strengthen Premium Entertainment
Key Takeaways Expanding global footprint, premium content partnerships, and diversified offerings are fueling growth, increased bargaining power, and improved margins in key established and emerging markets. Cost discipline and capital-light models are boosting sustained margin expansion, recurring cash flows, and flexibility for reinvestment or shareholder returns.
View narrative
US$32.82
FV
22.9% undervalued
intrinsic discount
8.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
5 days ago
author updated this narrative
ANI Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Key Takeaways Multiyear revenue growth is driven by expanding Cortrophin Gel potential, new product launches, and increasing adoption among previously untapped prescribers. Strategic investments in U.S. manufacturing, rare diseases, and complex generics strengthen margins, diversify the portfolio, and support resilience against supply chain and regulatory risks.
View narrative
US$90.50
FV
3.3% undervalued
intrinsic discount
9.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
EDAP TMS
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Rising Health Spending And Aging Populations Will Boost HIFU Utilization
Key Takeaways Focal One's innovative, minimally invasive platform and AI integration position EDAP as a leader in women's health and technology-driven treatments, broadening its global market reach. Expanding clinical evidence, hospital partnerships, and new treatment indications are poised to drive rapid adoption, high-margin recurring revenues, and sustainable long-term growth.
View narrative
US$14.00
FV
90.3% undervalued
intrinsic discount
13.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Agenus
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Precision Medicine And Global Aging Will Revolutionize Cancer Care
Key Takeaways Multiple transformative financing options and imminent investments could rapidly strengthen balance sheets and accelerate R&D, removing near-term funding concerns. Promising immunotherapy data, strong leadership, and strategic flexibility position the company for rapid market expansion, multi-indication approvals, and potential acquisition interest.
View narrative
US$23.00
FV
79.9% undervalued
intrinsic discount
13.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Sportsman's Warehouse Holdings
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Sun Belt Trends And Digital Adoption Will Unlock Outdoor Opportunities
Key Takeaways Strategic focus on hunting, fishing, and exclusive brands, combined with digital growth and localized inventory, is driving industry-beating growth and improved profitability. Strong presence in high-growth regions and omnichannel initiatives are expanding market share, boosting margins, and enhancing long-term store productivity.
View narrative
US$4.25
FV
36.5% undervalued
intrinsic discount
2.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Karyopharm Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Global Secular Trends Will Drive Adoption Of Targeted Oncology Therapies
Key Takeaways Breakthrough clinical outcomes and wide physician interest could drive substantially higher adoption and long-term revenue growth than current expectations. Expansion into biomarker-driven and underserved oncology markets creates potential for major new revenue streams and attractiveness for strategic partnerships or acquisitions.
View narrative
US$66.25
FV
91.1% undervalued
intrinsic discount
34.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
OptimizeRx
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Digital Health Adoption And AI Will Drive Secular Expansion
Key Takeaways Rapid scaling of high-margin subscription offerings and AI-driven tools is positioning the company for outsized, sustained profitability with expanding margins. Strong market embedment and financial discipline create flexibility for strategic acquisitions and innovation, supporting long-term growth above industry averages.
View narrative
US$27.00
FV
37.6% undervalued
intrinsic discount
12.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
GrowGeneration
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Cannabis Legalization And Global E-Commerce Will Expand Cultivation Supply Markets
Key Takeaways Proprietary product growth and accelerated digital platform adoption could rapidly enhance profitability and outpace competitor performance. Strategic acquisitions and international expansion offer diversification, access to emerging markets, and potential for substantial long-term revenue gains.
View narrative
US$2.50
FV
42.0% undervalued
intrinsic discount
-3.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies